| Management target | Revenue 50.0% FY27 |
|---|
| Revenue growth | Q2 operating income up over 50% YoY per management |
|---|---|
| Margins | Q2 EBITDA margin 18.02% vs 17.91% Q1; PAT margin 13.21%. |
| Demand visibility | CDMO commercial supplies; ₹100-130 Cr incremental FY27 revenue expected. |
| Management confidence | Confident; reiterated FY27 guidance and 'strong validation' language |
Growth
Q2 operating income grew over 50% YoY. H1 FY27 operating revenue ₹420.97 Cr, up 35.79%; H1 EBITDA over 4x.
Outlook
Reiterated FY27 revenue growth above 50%, 20-25% medium-term CAGR and 200-300 bps EBITDA margin expansion. ₹250 Cr capex funded internally.
Risks
Europe is 47% of revenue, so concentration is high. Samba EU-GMP/PIC/S upgrade is still underway, and raw material costs are a watch item.
Last quarter's promises, checked
Delivered
- Sustainable ~18% EBITDA → Q2 18.02% (= BEAT)
Partly delivered
- FY27 >50% growth (₹900 Cr) → H1 +35.79% (= PARTIAL)
- Samba EU-GMP upgrade 'on plan' → still underway, no date (= PARTIAL)
- Clarithromycin FY27 launch → validated, not launched (= PARTIAL)
Missed
- Q2 EBITDA >20% internal aim → Q2 18.02% (= MISS)
- CDMO FY27 ₹200-220 Cr → cut to ₹100-130 Cr (= MISS)
- CDMO ~45% of ₹750 Cr exports → CMO 26.99% of total sales (= MISS)
Investor Presentation filed with NSE, NSE: INDSWFTLAB. Summary written with AI assistance from the document.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹348.20
- Market cap
- ₹3,028 Cr
- Revenue (annual)
- ₹649.1 Cr
- Net profit (annual)
- ₹43.12 Cr
- P/E (TTM)
- 36.2×Sector 43.0×
- Promoter holding
- 42.93%+0.00% QoQ
- FII holding
- 10.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Other Announcement
Ind-Swift Laboratories Limited submitted its quarterly monitoring agency report for the period ended September 30, 2026. The report covers the utilization of Rs. 137.20 Crore raised via warrants.
Ind-Swift Laboratories Convertible Warrants
Ind-Swift Laboratories has fully utilized the Rs. 314.60 Crore proceeds from its preferential issue of convertible warrants. The monitoring agency CARE Ratings confirms no deviations in fund usage.
- Value
- ₹314.6 Cr
Ind-Swift Laboratories Results Update
Ind-Swift Laboratories reported Q2 FY27 revenue up 50% to ₹234.89 crore and PAT up 3.5x to ₹31.03 crore. Operating EBITDA margin rose to 18.02%.
Ind-Swift Laboratories Q2 FY27 Results: Net Profit ₹34.2 Cr, Up 327.5% YoY
Ind-Swift Laboratories Ltd reported revenue from operations of ₹240.5 Cr (+51.6% YoY) and net profit of ₹34.2 Cr (+327.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹34.2 Cr · +327.5% YoY
Ind-Swift Laboratories Board Meeting Date
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.
Ind-Swift Laboratories Convertible Warrants
Essix Biosciences Limited acquired 14,00,000 equity shares of Ind-Swift Laboratories Limited following the conversion of fully convertible warrants. The company disclosed this under SEBI regulations.